BR112018067536A2 - sistema de transpóson e métodos de uso - Google Patents

sistema de transpóson e métodos de uso

Info

Publication number
BR112018067536A2
BR112018067536A2 BR112018067536A BR112018067536A BR112018067536A2 BR 112018067536 A2 BR112018067536 A2 BR 112018067536A2 BR 112018067536 A BR112018067536 A BR 112018067536A BR 112018067536 A BR112018067536 A BR 112018067536A BR 112018067536 A2 BR112018067536 A2 BR 112018067536A2
Authority
BR
Brazil
Prior art keywords
methods
immune cell
transposon system
sequence encoding
dna sequence
Prior art date
Application number
BR112018067536A
Other languages
English (en)
Inventor
Hermanson David
Shedlock Devon
Ostertag Eric
Original Assignee
Poseida Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poseida Therapeutics Inc filed Critical Poseida Therapeutics Inc
Publication of BR112018067536A2 publication Critical patent/BR112018067536A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

trata-se de métodos para a modificação genética ex-vivo de uma célula imune que compreende entregar à célula imune, (a) uma sequência de ácidos nucleicos ou aminoácidos que compreende uma sequência que codifica uma enzima transposase e (b) uma sequência de dna sem ocorrência natural e recombinante que compreende uma sequência de dna que codifica um transpóson.
BR112018067536A 2016-02-26 2017-02-24 sistema de transpóson e métodos de uso BR112018067536A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662300387P 2016-02-26 2016-02-26
PCT/US2017/019531 WO2017147538A1 (en) 2016-02-26 2017-02-24 Transposon system and methods of use

Publications (1)

Publication Number Publication Date
BR112018067536A2 true BR112018067536A2 (pt) 2019-02-05

Family

ID=58314517

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018067536A BR112018067536A2 (pt) 2016-02-26 2017-02-24 sistema de transpóson e métodos de uso

Country Status (12)

Country Link
EP (1) EP3420090A1 (pt)
JP (1) JP2019506177A (pt)
KR (1) KR20180131545A (pt)
CN (1) CN109312361A (pt)
AU (1) AU2017224111A1 (pt)
BR (1) BR112018067536A2 (pt)
CA (1) CA3015642A1 (pt)
IL (1) IL261343A (pt)
MX (1) MX2018010288A (pt)
RU (1) RU2018133691A (pt)
SG (1) SG11201807134RA (pt)
WO (1) WO2017147538A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190119636A1 (en) * 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
US11278570B2 (en) 2016-12-16 2022-03-22 B-Mogen Biotechnologies, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
WO2018112415A1 (en) 2016-12-16 2018-06-21 B-Mogen Biotechnologies, Inc. ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS
CN108728477B (zh) * 2017-04-24 2022-02-22 华东理工大学 一种高效的转座突变***及构建方法
US20210115453A1 (en) * 2017-08-31 2021-04-22 Poseida Therapeutics, Inc. Transposon system and methods of use
WO2019051424A2 (en) * 2017-09-08 2019-03-14 Poseida Therapeutics, Inc. COMPOSITIONS AND METHODS FOR CONDITIONAL GENE EXPRESSION MEDIATED BY A CHIMERIC LIGAND RECEPTOR (CLR)
US10329543B2 (en) 2017-10-23 2019-06-25 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
CA3104288A1 (en) 2018-06-21 2019-12-26 B-Mogen Biotechnologies, Inc. Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods
EP3920941A4 (en) * 2019-02-08 2023-01-18 Dna Twopointo Inc. TRANSPOSON-BASED MODIFICATIONS OF IMMUNE CELLS
CN111926041B (zh) * 2020-10-16 2020-12-25 广州吉妮欧生物科技有限公司 一种SARS-CoV-2假病毒小鼠体内包装***及其制备方法
CN114246986B (zh) * 2021-12-29 2022-08-23 中国人民解放军陆军军医大学 一种基于原位调控免疫反应的心血管植入物及其制备方法
CN116590341A (zh) * 2023-07-13 2023-08-15 山东维真生物科技有限公司 一种腺病毒-PiggyBac***及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US9228180B2 (en) 2007-07-04 2016-01-05 Max-Delbruck-Centrum Fur Molekulare Medizin Polypeptide variants of sleeping beauty transposase
US20110311506A1 (en) * 2009-02-25 2011-12-22 The Johns Hopkins University Piggybac transposon variants and methods of use
WO2010099296A1 (en) * 2009-02-26 2010-09-02 Transposagen Biopharmaceuticals, Inc. Hyperactive piggybac transposases
US20130045491A1 (en) * 2011-07-19 2013-02-21 Derya Unutmaz Methods for activating t cells
WO2014077863A1 (en) * 2012-11-19 2014-05-22 Nature Technology Corporation Replicative minicircle vectors with improved expression

Also Published As

Publication number Publication date
MX2018010288A (es) 2019-06-06
KR20180131545A (ko) 2018-12-10
JP2019506177A (ja) 2019-03-07
IL261343A (en) 2018-10-31
WO2017147538A1 (en) 2017-08-31
SG11201807134RA (en) 2018-09-27
EP3420090A1 (en) 2019-01-02
CA3015642A1 (en) 2017-08-31
RU2018133691A3 (pt) 2020-07-29
AU2017224111A1 (en) 2018-09-13
CN109312361A (zh) 2019-02-05
RU2018133691A (ru) 2020-03-26

Similar Documents

Publication Publication Date Title
BR112018067536A2 (pt) sistema de transpóson e métodos de uso
BR112020024863A2 (pt) Nucleases guiadas por rna, fragmentos ativos e variantes das mesmas e métodos de uso
GB2569733A (en) RNA-guided nucleic acid modifying enzymes and methods of use thereof
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
CY1124921T1 (el) Μεθοδοι για την εκχυλιση και τον καθαρισμο μη μετουσιωμενων πρωτεϊνων
EP4303314A3 (en) Polypeptide tagged nucleotides and use thereof in nucleic acid sequencing by nanopore detection
AU2016262093A8 (en) Enhancing endonuclease based gene editing in primary cells
WO2016046234A3 (en) Recombinant phe-free proteins for use in the treatment of phenylketonuria
SG10201906673WA (en) Artificial nucleic acid molecules
BR102014027466A8 (pt) Sequência recombinante, uso de uma planta, uma parte de planta, ou uma célula de planta de soja, método para preparação de uma célula de planta transgênica, e loci genômicos de soja não gênicos purificados
EP3234200A4 (en) Compositions and methods for targeted depletion, enrichment, and partitioning of nucleic acids using crispr/cas system proteins
EP4219744A3 (en) Methods of preparing nucleic acids for sequencing
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
MX2021010668A (es) Proteinas de fusion de citoquinas.
EA201690529A1 (ru) Способы модификации клетки-хозяина
BR112016027196A2 (pt) cepa bacteriana gram-negativa recombinante, vetor, método para liberar uma proteína heteróloga em uma célula eucariótica, método para purificar uma proteína heteróloga e uso de uma cepa bacteriana gram-negativa recombinante
MX2019004487A (es) Metodos y composiciones para el tratamiento de la enfermedad de fabry.
WO2016065349A8 (en) Short non-coding protein regulatory rnas (sprrnas) and methods of use
BR112017016897A2 (pt) cepas fúngicas e métodos de uso
BR112018010639A2 (pt) método de transfecção transitória para produção retroviral.
CU24405B1 (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros
EP4353830A3 (en) Methods of nucleic acid sample preparation for analysis of cell-free dna
MY191539A (en) Streptococcal vaccine
EA201691011A1 (ru) Последовательность модифицированного эндолизина el188
BR112018001121A2 (pt) vetor recombinante do vírus orf (orfv), célula, composição, uso de um vetor recombinante de orfv, e, molécula de ácido nucleico

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2711 DE 20-12-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.